Abstract-Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor, inhibits the inactivation and degradation of glucagon like peptide 1 (GLP-1), which is used for the treatment of type 2 diabetes mellitus. However, little is known about the role of GLP-1 in hypertension. This study investigated whether the activation of GLP-1 signaling protects endothelial function in hypertension. Two-week sitagliptin treatment (10 mg/kg per day, oral gavage) improved endotheliumdependent relaxation in renal arteries, restored renal blood flow, and reduced systolic blood pressure in spontaneously hypertensive rats. In vivo sitagliptin treatment elevated GLP-1 and GLP-1 receptor expressions, increased cAMP level, and subsequently activated protein kinase A, liver kinase B1, AMP-activated protein kinase-␣ and endothelial NO synthase in spontaneously hypertensive rat renal arteries. Inhibition of GLP-1 receptor, adenylyl cyclase, protein kinase A, AMP-activated protein kinase-␣, or NO synthase reversed the protective effects of sitagliptin. We also demonstrate that GLP-1 receptor agonist exendin 4 in vitro treatment had similar vasoprotective effects in spontaneously hypertensive rat renal arteries and increased NO production in spontaneously hypertensive rat aortic endothelial cells. Studies using transient expressions of wild-type and dominant-negative AMP-activated protein kinase-␣2 support the critical role of AMP-activated protein kinase-␣ in mediating the effect of GLP-1 in endothelial cells. Ex vivo exendin 4 treatment also improved endothelial function of renal arteries from hypertensive patients. Our results elucidate that upregulation of GLP-1 and related agents improve endothelial function in hypertension by restoring NO bioavailability, suggesting that GLP-1 signaling could be a therapeutic target in hypertension-related vascular events. Key Words: dipeptidyl peptidase 4 Ⅲ endothelium-dependent relaxation Ⅲ glucagon-like peptide 1 Ⅲ NO Ⅲ protein kinases Ⅲ spontaneously hypertensive rats H ypertension is caused by pathological changes in renal and vascular structure and function involved in blood pressure regulation.
H ypertension is caused by pathological changes in renal and vascular structure and function involved in blood pressure regulation. 1 Hypertension can cause renal damage if it is not properly controlled. 2 The impaired vasodilator response is a risk factor for renal function loss in patients with essential hypertension. 3 Persistent hypertension alters functional characteristics of vascular endothelial cells and is associated with impaired vasodilatory function. 4 Diminished production and function of endothelium-derived NO leads to endothelial dysfunction, 5 a crucial initial step culminating in vascular events in hypertension.
Dipeptidyl peptidase 4 (DPP-4), also known as CD26, is a ubiquitous enzyme detectable in the endothelium. 6 Glucagonlike peptide 1 (GLP-1) produced by L-type cells in the intestine, is a substrate for DPP-4. 7 GLP-1 improves glucose use in patients with type 2 diabetes mellitus by increasing insulin secretion and inhibiting glucagon secretion. 8, 9 Sitagliptin, a highly selective DPP-4 inhibitor, 10 inhibits the inactivation and degradation of GLP-1, 11 which is used for the treatment of type 2 diabetes mellitus as monotherapy or in combination with other antiglycemic agents, such as metformin. 12 The effect of GLP-1 on blood pressure has been reported in both animal and human hypertension. 13, 14 Treatment with GLP-1 receptor (GLP-1R) agonists leads to a transient blood pressure increase attributed to the impact on sympathetic outflow. 15 However, continuous infusion of GLP-1 produces a small but insignificant reduction of blood pressure in patients with type 2 diabetes mellitus. 16 Moreover, chronic administration of recombinant GLP-1 prevents the development of hypertension and improves endothelial function in Dahl salt-sensitive rats. 17 By contrast, the effect of DPP-4 inhibition on blood pressure is largely unknown, although limited studies show that DPP-4 inhibition by sitagliptin produces a small blood pressure-lowering effect in nondiabetic patients with hypertension on stable antihypertensive therapy. 18 The present study investigated whether DPP-4 inhibition could ameliorate endothelial dysfunction in renal arteries from hypertensive animals and patients, as well as possible signaling mechanisms involved.
Materials and Methods
A supplemental Methods section can be found in the online-only Data Supplement. 
Measurement and Analysis of Renal Blood Flow by MRI Acquisition Procedure
MRI studies were performed using a 3T clinical whole-body imaging system (Achieva, Philips Healthcare, Best, the Netherlands). 19 
Renal Artery Preparation and Functional Studies
Rats were euthanized by CO 2 suffocation, and renal interlobar arteries were removed and placed in ice-cold Krebs solution. Arteries were prepared, and changes of isometric tension were recorded. 
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Western Blot Analysis
NO Measurement
Intracellular NO production was monitored using a fluorescent NO indicator 4-amino-5-methylamino-2=,7=-difluorofluorescein diacetate 22 and the Total Nitric Oxide Assay kit.
Data Analysis
Results represent meanϮSEM from different rats or patients. Statistical significance was determined by 2-tailed Student t test or 1-way ANOVA followed by the Bonferroni post hoc test when Ͼ2 treatments were compared. P values Ͻ0.05 indicate statistically significant difference.
Results
Sitagliptin Treatment Lowers Blood Pressure and Increases Renal Blood Flow in Spontaneously Hypertensive Rats
Ambulatory arterial pressure in conscious, unrestrained spontaneously hypertensive rats (SHRs) was monitored by radiotelemetry. The ambulatory systolic blood pressures (SBP) were significantly lower in 2-week sitagliptin-treated SHRs compared with vehicle-treated SHRs (averaged SBP, 160Ϯ8 versus 180Ϯ5 mm Hg; nϭ4 each group), whereas sitaglitin treatment did not alter SBPs in Wistar-Kyoto rats (WKYs; averaged SBP, 120Ϯ4 versus 119Ϯ4 mm Hg; nϭ4 each group; Figure 1A ). This is further confirmed by the direct measurement of SBP with a direct catheter in anesthetized rats ( Figure S1A , available in the online-only Data Supplement) and the tail-cuff method ( Figure S1B ). However, sitagliptin treatment did not significantly lower mean arterial blood pressure or diastolic blood pressure in all groups of rats. It is noted that the effect of sitagliptin on SBP in SHRs was a step decrease that occurred between days 3 and 4 and that there was no diurnal rhythm in control and sitagliptin-treated rats ( Figure S1C ). Renal blood flow (RBF) reduction in SHRs was restored by 2-week sitagliptin therapy ( Figure 1B ).
Sitagliptin Improves Endothelial Function in SHR Renal Arteries
Two-week sitagliptin administration increased the plasma concentration of GLP-1 in WKYs and SHRs ( Figure S2A Figure 3E ), exendin 9-39 (100 nmol/L), compound C (10 mol/L), and N G -nitro-L-arginine methyl ester (100 mol/L; NO synthase inhibitor; Figure 4E ) also inhibited the improved EDR. Sitagliptin treatment in vivo increased cAMP levels in SHR renal arteries, which were inhibited by exendin 9-39 (100 nmol/L) and SQ22536 (100 mol/L) but not by compound C (10 mol/L; Figure S3 ). 
Exendin 4 Improves Endothelium-Dependent Relaxation in SHR Renal Arteries
GLP-1R agonist exendin 4 (10 nmol/L; 12 hours) increased acetylcholine-induced EDR in SHR renal arteries, which were reversed by coincubation with SQ22536 (100 mol/L) and H89 (1 mol/L; Figure 5A ) or compound C (10 mol/L) and N G -nitro-L-arginine methyl ester (100 mol/L; Figure  5B ) or exendin 9-39 (100 nmol/L) and GLP-1R antibody (2.5 g/mL; Figure 5C ). By contrast, exendin 4 treatment for 12 hours had no effect on EDR in WKYs ( Figure 5D ).
Exendin 4 Increases AMPK␣ and eNOS Phosphorylations and Stimulates NO Production in SHR Aortic Endothelial Cells
Exendin 4 (10 nmol/L) stimulated NO production in primary SHR aortic endothelial cells, which was inhibited by pretreatment with exendin 9-39 (100 nmol/L), SQ22536 (100 mol/L), Figure S4 and S5). Twelve-hour ex vivo treatment with either exendin 4 (10 nmol/L) or sitagliptin (10 mol/L) increased the cGMP level in SHR renal arteries ( Figure  S6 ). Transient overexpression of AMPK␣2 by wild-type AMPK␣2 further increased AMPK␣ and eNOS phosphorylations ( Figure S7 ) and NO production ( Figure S4D ) in response to exendin 4 in endothelial cells, whereas suppression of the AMPK activity by dominant-negative AMPK␣2 (K45R mutated) inhibited such effects. The level of AMPK␣2 increased significantly in SHR endothelial cells by expression of wild-type AMPK but not dominant-negative AMPK ( Figure S8 ).
Sitagliptin Ameliorates Endothelial Dysfunction in Renal Arteries From Hypertensive Patients
EDRs were impaired in renal arteries from hypertensive patients compared with those from normotensive patients, whereas exendin 4 (10 nmol/L; 12 hours) improved EDRs in renal arteries from hypertensive patients ( Figure 6A ). The reduced GLP-1R level ( Figure 6B ) and decreased phosphorylations of PKA C, LKB1, AMPK␣, and eNOS ( Figure  6C through 6F) were elevated by exendin 4 in these arteries.
Discussion
The present study demonstrated a functional importance of GLP-1 and GLP-1R in the regulation of endothelial function in SHR renal vasculature. The major novel findings include the following: (1) treatment with sitagliptin in vivo and exendin 4 ex vivo improved endothelial function in SHR renal arteries via the sequential activation of the PKA/LKB1/AMPK␣/eNOS axis; (2) exendin 4 stimulated NO production in SHR aortic endothelial cells and improved endothelial function in renal arteries from hypertensive patients; (3) GLP-1R expression was reduced in SHR renal arteries, which was upregulated by chronic sitagliptin treatment; and (4) 2-week oral administration of sitagliptin to SHR lowered SBP and improved RBF without affecting glucose metabolism ( Figure S9 ). Our study reveals a protective role of GLP-1 and related agents in improving endothelial function in hypertension through the activation of AMPK␣.
Clinical and experimental studies suggest that GLP-1 and its analogs confer cardiovascular protection through favorable modulation of heart rate, blood pressure, and cardiac hemodynamic responses. 15, 23, 24 The present study shows that in vivo sitagliptin or in vitro exendin 4 treatment improved the impaired EDR in SHR or hypertensive patients and stimulated NO production in primary SHR aortic endothelial cells, which is likely mediated by AMPK␣/eNOS activation. To further confirm the role of AMPK␣, the present study show that the suppression of AMPK␣2 activity by dominantnegative AMPK␣2 in SHR endothelial cells inhibited the AMPK␣/eNOS phosphorylations and NO production triggered by exendin 4, whereas increasing the AMPK␣ activity by wild-type AMPK overexpression enhanced the stimulatory effect of exendin 4. AMPK, which is one of the principal kinases responsible for phosphorylation and activation of eNOS, also mediates the vasoprotective effects of metformin and berberine in endothelial cells. [25] [26] [27] [28] In the present study, we used 3 assay methods, including N G -nitro-L-arginine methyl estersensitive EDR in renal arteries, eNOS phosphorylation, and NO production, to support that NO bioavailability was increased by sitagliptin or exendin 4 treatment. NO levels in SHR endothelial cells were detected by the use of 4-amino-5-methylamino-2=,7=-difluorofluorescein fluorescence 29 and the Total Nitric Oxide Assay kit. 30 After release, NO acts on vascular smooth muscle cells to stimulate the activity of soluble guanylate cyclase, an enzyme that catalyzes the chemical conversion of GTP into cGMP. 31 Therefore, we measured cGMP levels in SHR renal arteries that were elevated by 12-hour ex vivo incubation with exendin 4 or sitagliptin and thus confirmed the increased NO production ( Figure S6 ). The present results suggest that GLP-1-elevating agents could be a novel upstream regulator of AMPK␣ to preserve the NO bioavailability and endothelial function in hypertension.
GLP-1R is expressed in human coronary artery endothelial cells, 32 as well as in the endothelium and smooth muscle cells, 23 which were shown to be downregulated by hyperglycemia, and this decrease likely contributed to the impaired incretin effects in diabetes mellitus. 33 The present study shows that GLP-1R expression was reduced in SHR renal arteries, whereas in vivo sitagliptin treatment increased the expression of GLP-1R, supporting that DPP-4 inhibition restores the expression and function of GLP-1/GLP-1R in SHR arteries. However, the mechanism of GLP-1R downregulation in hypertension needs to be further elucidated.
The actions of GLP-1R are thought to involve cAMP production and PKA activation. 23 , 34 Kieffer and Habener suggested the role of the GLP-1R and cAMP in the actions of GLP-1 on vascular endothelium. Moreover, PKA stimulates LKB1 for AMPK activation in hepatocytes. 36 The present study demonstrated that sitagliptin stimulated the activation of LKB1/AMPK␣ subsequent to cAMP/PKA signaling on activation of GLP-1R ( Figure S10) . Finally, the in vivo effect of sitagliptin was assessed in SHRs by measuring RBF and blood pressure. Chronic GLP-1 treatment lowers blood pressure in patients with type 2 diabetes mellitus, 37 and exendin 4 also exerts an antihypertensive effect in salt-sensitive hypertensive mice. 13, 17 Another study suggests that DPP-4 inhibition by sitagliptin attenuates blood pressure elevation in young SHRs by diminishing proximal tubule sodium reabsorption. 38 In the present study, we observe that 2-week sitagliptin treatment reduced SBP in adult SHRs. The restoration of AMPK␣/eNOS in SHR arteries after sitagliptin treatment might also contribute in part to blood pressure reduction. 39, 40 Renal function is of importance in controlling blood pressure in the development of essential hypertension, 3 and RBF is a parameter of renal function. 40 RBF is reduced in renovascular beds in essential hypertension, which is attributed to arteriolar constriction. 41 SHRs are known to have higher mean arterial pressure and renal vascular resistance than WKYs under baseline conditions. Moreover, NO synthase inhibition induced hypertension 42 and caused more reduction of RBF in SHRs, 43 suggesting that RBF is closely related to the NO availability in renal circulation. The present study showed that RBF was reduced in SHRs compared with WKYs, and 2-week sitagliptin treatment increased RBF in SHRs, which may in part contribute to the blood pressurelowering effect of sitagliptin.
Perspectives
We demonstrate that DPP-4 inhibition by sitagliptin preserves vascular GLP-1/GLP-1R function in SHRs, a genetic model of hypertension. GLP-1-induced AMPK␣/eNOS activation restores endothelium-dependent relaxation and RBF, thus helping to reduce SBP in SHRs. Like sitagliptin, the GLP-1R agonist exendin 4 is also effective in augmenting endothelial function in hypertensive rats and patients, thereby elucidating the mechanism underlying the vascular benefits of GLP-1 and related agents. Taken together, the novel findings of the present study highlight the prospect for the use of GLP-1-elevating agents and GLP-1R agonists against vascular dysfunction in hypertension. 
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Novelty and Significance
What Is New?
• Treatment with the dipeptidyl peptidase 4 inhibitor sitagliptin and GLP-1 receptor agonist exendin 4 improves endothelial function.
• Sitagliptin treatment lowers SBP and enhances RBF in spontaneously hypertensive rats.
• Sitagliptin treatment increases vascular GLP-1 receptor expression.
• Exendin 4 stimulates NO production and improves endothelial function in hypertensive patients.
What Is Relevant?
• The novel findings of the present study highlight the prospect for the use of GLP-1--elevating agents and GLP-1 receptor agonists against vascular dysfunction in hypertension.
Summary
The upregulation of GLP-1 and related agents preserves endothelial function in hypertension by restoring NO bioavailability. 
Liu et al DPP-4 Inhibition Restores Endothelial Function
Blood Pressure Measurement
SHRs were surgically implanted with telemetric transmitters (TL11M2-C50-PXT, Data Sciences International, Minnesota, USA). The catheter of the implant was placed into the distal portion of the descending aorta. Rats were allowed to recover from surgery for 7 days, and then 24h ambulatory systolic blood pressures were measured by telemetry in conscious, unrestrained rats. Data were collected for 20 seconds every 20 min and used the 24-hour mean values for analysis. The ambulatory arterial pressures were measured at Day 0 and Day 14 after sitagliptin treatment in SHRs and WKYs. For direct catheter measurement, vehicle and sitagliptin-treated WKY and SHR were anesthetized.
Systolic blood pressure was measured by inserting a heparinized saline-filled PE-50 catheter into the left common carotid artery after an initial 15 min equilibration period. 1 In addition, systolic blood pressure was also measured by the tail-cuff method before and after sitagliptin treatment. Blood pressure was calculated from the average of 5 successive recordings.
Measurement of Renal Blood Flow by Magnetic
Resonance Image (MRI) Acquisition Procedure MRI studies were performed using a 3T clinical whole-body imaging system (Achieva, Philips Healthcare, Best, Netherlands). MRI contrast agent was gadolinium-tetraazacyclododecanetetraacetic acid (Gd-DOTA) (Guerbet Group, Roissy CDG cedex, France). After anesthesia, rats were positioned supinely. The MRI acquisition of the rat urinary system included high resolution T2 weighted axial plane anatomical examination, high resolution T1 weighted coronal plane anatomical examination, and dynamic contrast enhanced examination in coronal plane. Axial anatomical examinations were acquired with the following parameters: multiple slice turbo spine echo sequence, repetition time (TR)/ time to echo (TE)/flip angle= 2359 ms/120 ms/90°, field of view = 60 mm×81 mm×30 mm, the acquisition voxel size was 0.41 mm×0.41 mm×1.50 mm, and the reconstructed voxel size was 0.17 mm×0.17 mm×1.5 mm. Coronal anatomical examinations were acquired with the following parameters: three-dimensional (3D) gradient echo sequence with fat suppression, TR/TE/flip angle= 4.4 ms/2.2 ms/10°, field of view = 80 mm× 80 mm×18 mm, the acquisition voxel size was 0.50 mm×0.50 mm×1.00 mm and the reconstructed voxel size was 0.28 mm×0.28 mm×0.50 mm. The contrast-enhanced examinations were acquired with the following parameters: 3D gradient echo sequence, TR/TE/flip angle= 6.8 ms/2.3 ms/35°, field of view = 80 mm×80 mm×12 mm, the acquisition voxel size was 0.61 mm×0.75 mm×3.00 mm and the reconstructed voxel size was 0.31 mm×0.31 mm×1.5 mm. MRI contrast agent was gadoliniumtetraazacyclododecanetetraacetic acid (Gd-DOTA) (Guerbet Group, Roissy CDG cedex, France). A dose of 0.075 mmol/kg was injected through tail vein as a rapid bolus in less than 1 sec after initial baseline 10 acquisitions and followed by a flush of 0.5 mL normal saline. Dynamic scan was stopped when the contrast agent was excreted and clearly visible in the bilateral ureters.
MRI Analysis
The reconstructed MR images were transferred to a radiological workstation (Extended Workspace, Philips, Best, Netherlands) for off-line analysis. Anatomical images were read by a radiologist with animal research experiences. For analysis of dynamic data, regions of interest (ROIs) were manually drawn over left and right kidneys. The ROIs of the renal cortex were drawn in all rats. These ROIs were used on the perfusion-weighted data to generate time signal intensity curves.
Intrarenal Artery Preparation
Rats were sacrificed by CO 2 suffocation and intrarenal arteries were removed and placed in ice-cold Krebs solution (mmol/L): 119 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1 MgCl 2 , 25 NaHCO 3 , 1.2 KH 2 PO 4 , and 11 D-glucose. Arteries were cleaned of adhering tissue and cut into ring segments of 2 mm in length. Arteries from SHR were incubated for 12 hours in Dulbecco's Modified Eagle's Media (DMEM, Gibco, Grand Island, NY, USA) culture media with 10% fetal bovine serum (FBS, Gibco), 100 IU penicillin and 100 μg/mL streptomycin with or without sitagliptin or exendin-4. Rings were suspended in myograph (Danish Myo Technology, Aarhus, Denmark) for recording of changes in isometric tension. 2, 3 Briefly, two tungsten wires (40 µm in diameter) were inserted through the lumen and fixed to jaws of organ chamber. The organ chamber was filled with 5 mL Krebs solution and gassed by 95% O 2 -5% CO 2 at 37°C (pH ~7.4). Each ring was stretched to 2.5 mN, an optimal tension, and then allowed to stabilize for 90 min before the start of each experiment. 
Functional Studies
Each ring was initially contracted by 60 mmol/L KCl. Endothelium-dependent relaxation (EDR) to acetylcholine (ACh, 0.003 to 10 μmol/L) while endothelium-independent relaxation to sodium nitroprusside (SNP, 0.001 to 10 μmol/L) were examined in arteries pre-contracted with phenylephrine (1 μmol/L). In the first set of experiments, SHR renal arteries were incubated with exendin-4 (10 nmol/L, GLP-1 receptor agonist) for 12 hours before vasoreactivity study on wire myograph. In some experiments, GLP-1 receptor antibody (2.5 μg/mL) was added 2 hours before incubation with exendin-4 or incubation with SQ22536 (100 μmol/L, adenylate cyclase inhibitor), H89 (1 μmol/L, PKA inhibitor), exendin 9-39 (100 nmol/L, GLP-1 receptor antagonist) and compound C (10 μmol/L, AMPKα inhibitor) along with exendin-4. Some arterial rings were subjected to 30-min exposure to L-NAME (100 μmol/L, nitric oxide synthase inhibitor) and then endothelium-dependent relaxations in response to cumulative additions of ACh were measured. The second series of experiments examined the impact of oral treatment with sitagliptin on endothelial function in SHRs. The relaxations to ACh in renal arteries from sitagliptin-treated SHRs were studied in control and in the presence of each of the following inhibitors (30-min incubation): SQ22536 (100 μmol/L), H89 (1 μmol/L), exendin 9-39 (100 nmol/L), 4 compound C (10 μmol/L), 5 or L-NAME (100 μmol/L).
Measurement of GLP-1 in Plasma
Plasma was kept from vehicle and sitagliptin-treated WKYs and SHRs. GLP-1 levels in plasma were assayed by Glucagon-Like Peptide-1 (Active) ELISA kit (Linco Research) according to the manufacturer's instructions.
cAMP Levels in Renal Arteries
Renal arteries from sitagliptin-treated SHR were cultured with or without inhibitors and were prepared according to the manufacturer's instructions. cAMP levels were assayed by Direct cAMP ELISA Kit (Enzo Life Sciences, Farmingdale, NY, USA).
Primary Culture of Rat Aortic Endothelial Cells
Aortas of SHR were dissected in sterilized phosphate buffered saline (PBS) under a stereoscopic microscope. After digestion by 0.2% collagenase for 15 minutes at 37°C, RPMI-1640 (Gibco) was added and endothelial cells were then collected by centrifugation at 1000 rpm for 5 minutes. Thereafter, the pellet was gently re-suspended in RPMI-1640 supplemented with 10% FBS and cultured in a 75-cm2 cell culture flask. To remove other cell types, the medium was changed after 1-hour incubation, then maintained until 70% confluence before use.
Transfection Condition
SHR aortic endothelial cells were transfected with either a wild type AMPKα2 plasmid (WT-AMPK), a dominant negative AMPK construct K45R (DN-AMPK), or control vector by electroporation using Nucleofector II machine (Amaxa/Lonza, Walkersville, MD, USA) according to the manufacturer's instruction. About 70% of endothelial cells were successfully transfected as indicated by control transfection using a GFPexpressing pCAGGS vector.
Western Blot Analysis
Isolated renal arteries or SHR aortic endothelial cells were homogenized in RIPA lysis buffer that contained 1 µg/mL leupeptin, 5 µg/mL aprotinin, 100 µg/mL PMSF, 1 mmol/L sodium orthovanadate, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L sodium fluoride, and 2 µg/mL β-glycerolphosphate, and centrifuged at 20,000 ×g for 20 min at 4°C. Protein lysates (25 μg for arteries, 10 μg for cells) were separated by electrophoresis and transferred onto PVDF membrane. Blots were blocked with 1% bovine serum albumin or 5% non-fat milk for 1 hour and incubated overnight at 4°C with antibodies against phospho-PKA C (catalytic subunit, Thr 
Nitric Oxide (NO) Measurement
Endothelial cells seeded on glass coverslips were loaded with 1 μmol/L DAF-FM diacetate (Molecular Probes, Eugene, OR, USA) at room temperature for 10 minutes and placed in a designed chamber for fluorescence imaging. Intracellular NO production was monitored using a fluorescent NO indicator DAF-FM diacetate as described. 6 DAF-FM diacetate is cellpermeant and passively diffuses across cellular membrane. The fluorescence quantum yield of DAF-FM is ~0.005, but increases ~160 fold to ~0.81, after reacting with NO, which was measured by a confocal scanning unit (FV1000, Olympus, Tokyo, Japan) at excitation 488 nm and an emission filter of 505-525 nm. Changes in [NO] i were displayed as a ratio of fluorescence relative to the intensity (F 1 /F 0 ), and analyzed by the Fluoview software (Olympus).
Total NO Production in Endothelial Cells
SHR endothelial cells were incubated in the presence of exendin-4 (10 nmol/L, 30min) with or without inhibitors. Total NO production in SHR endothelial cells was determined by measuring the concentration of nitrate and nitrite, a stable metabolite of NO, by the Total Nitric Oxide Assay Kit (Beyotime Biotechnology) according to the manufacturer's instructions. cGMP Levels in Renal Arteries SHR renal arteries were cultured with sitagliptin (10 μmol/L) or exendin-4 (10 nmol/L) for 12 hours. The tissue were then frozen and stored at -80 °C until assay. The levels of cyclic GMP were measured by direct cGMP ELISA Kit (Enzo Life Sciences, Farmingdale, NY, USA) according to the manufacturer's instruction. The result was expressed as cyclic GMP production in pmol per mg protein.
Human Artery Specimen
The present study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee. Human renal arteries were obtained after informed consent from normotensive and hypertensive patients undergoing nephrectomy at ages between 50-80 years old. The indications for surgery included tumor (4 in normotensive patients and 3 in hypertensive patients) and poorly functioning kidney (2 in normotensive patients and 1 in hypertensive patients). History of hypertension was defined as having persistent elevated blood pressure, systolic blood pressure of >140 mm Hg, or diastolic blood pressure of >90 mm Hg and requiring medical therapy. Phenylephrine, acetylcholine, L-NAME, sodium nitroprusside, H89, compound C, exendin-4, exendin 9-39 were purchased from Sigma-Aldrich Chemical (St Louis, MO, USA). SQ22536 was from Calbiochem (San Diego, CA, USA). The cell culture media and DAF-FM diacetate were from Invitrogen (Carlsbad, CA, USA). Sitagliptin was a kind gift from Merck Research Laboratories (Rahway, NJ, USA). SQ22536 and compound C were dissolved in DMSO and other drugs in distilled water. DMSO (0.1% v/v) did not modify agonist-induced responses.
Materials and Drugs
Data Analysis
Results represent means±SEM from different animals. Concentration-response curves were analyzed by non-linear curve fitting using GraphPad Prism software (Version 4.0, San Diego, CA, USA). The negative logarithm of the dilator concentration that produced half of the maximum effect (pD 2 
